Lung cancer is a leading cause of cancer death due to the high incidence of metastasis; therefore, novel and effective treatments are urgently needed. A current strategy is cancer-specific targeted gene therapy. Although many identified that cancer-specific promoters are highly specific, they tend to have low activity compared with the ubiquitous cytomegalovirus (CMV) promoter, limiting their application. We developed a targeted gene therapy expression system for lung cancer that is highly specific with strong activity. Our expression vector uses the survivin promoter, highly expressed in many cancers but not normal adult tissues. We enhanced the survivin promoter activity comparable to the CMV promoter in lung cancer cell lines using an established platform technology, whereas the survivin promoter remained weak in normal cells. In mouse models, the transgene was specifically expressed in the lung tumor tissue, compared with the CMV promoter that was expressed in both normal and tumor tissues. In addition, the therapeutic gene BikDD, a mutant form of pro-apoptotic Bcl2 interacting killer, induced cell killing in vitro, and inhibited cell growth and prolonged mouse survival in vivo. Importantly, there was virtually no toxicity when BikDD was expressed with our expression system. Thus, the current report provides a therapeutic efficacy and safe strategy worthy of development in clinical trials treating lung cancer.
Introduction
Lung cancer remains the leading cause of cancer deaths in the world (Jemal et al., 2008) . New approaches to the treatment of lung cancer are urgently needed. Of the current methods, targeted gene therapy is a novel strategy for treatment of cancer, especially for treating unresectable, metastasized or therapy refractory tumors (Gunther et al., 2005) . To succeed in cancer gene therapy, the efficient delivery of therapeutic genes to a target site is a major challenge. Although viruses are very effective gene delivery systems, there are concerns for safety issue because of the immunogenicity of viral proteins, risk of oncogenesis and inadvertent creation of infectious viral particles (Russ and Wagner, 2007) . Rapid advances in transfection technologies using nonviral vectors, together with their relatively low toxicity, suggest that nonviral vectors may have significant potential for clinical applications (Huang et al., 2005) . Most gene therapy protocols use strong promoters such as the cytomegalovirus (CMV) promoter to drive a transgene to validate the biological activity of the gene of interest (Fitzsimons et al., 2002) . However, these types of strong promoters are usually ubiquitously expressed without tumor-targeting activity, thus limiting their applications because of the potential side effects caused by unwanted expression of therapeutic gene in normal tissue. This issue is especially critical when the therapeutic gene is delivered systemically such as by intravenous injection. One way to circumvent the non-specific delivery is to develop a strong cancerspecific expression vector. Most of the identified lung cancer-specific promoters exhibit a high level of lung cancer specificity but are still much weaker than the CMV promoter (Chen et al., 2004; Oshikiri et al., 2006; Fukazawa et al., 2007) . To overcome this issue, we have established a specific promoter amplification system called VP16-GAL4-WPRE integrated systemic amplifier (VISA) system (Xie et al., 2007) to significantly amplify the cancer-specific promoter activity to a comparable level to CMV in cancer cells, although still retaining low promoter activity in normal tissues. This VISA system combined with pancreatic cancer-specific promoter to target expression of pro-apoptotic gene exhibited significant antitumor effects on pancreatic cancer.
Survivin is a member of the inhibitors of apoptosis protein family that have an important role in both control of cell division and inhibition of apoptosis (Ambrosini et al., 1997) . Survivin is strongly expressed in embryonic, fetal organs and common cancers, but has not been reported in differentiated normal tissues with exception of the thymus, basal colonic epithelium (Altieri, 2003a) and neural stem cells during angiogenesis (O'Connor et al., 2000) . Owing to its upregulation in most human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a novel therapeutic target (Zaffaroni et al., 2005) . Our previous results also showed that the survivin promoter possessed high activity in lung cancer cells and low activity in other cell types, including immortalized normal cell lines and other cancer types (Chen et al., 2004) , suggesting that survivin may be a good cancer-specific promoter in cancer gene therapy. In addition, we have developed a Bcl2 interacting killer (Bik) mutant, BikDD, in which threonine 33 and serine 35 were changed to aspartic acid to mimic the phosphorylation at these two residues, and found the mutant's anti-cancer activity to be more potent than wild-type Bik (Li et al., 2003; Day et al., 2006; Xie et al., 2007) . Here, we show that the therapeutic effect becomes more significant through combining cancer-specific promoter, survivin, with the promoter amplification VISA system to enhance transgene, BikDD expression in lung cancer cells. In addition, this vector produced virtually no toxicity compared with the CMV promoter vector. Thus, this survivin-VISA expression vector in combination with the therapeutic gene BikDD may be a promising candidate for clinical trials in the near future.
Results

Enhancement of survivin promoter activity by the VISA system
To assess whether the VISA system can selectively enhance transgene expression driven by the survivin promoter in lung cancer cells, but not in normal cells, three promoters, survivin, survivin combined with VISA system (survivin-VISA) and CMV were used to drive luciferase expression ( Figure 1a ). A panel of non-smallcell lung cancer cell lines and normal cell lines were used to detect the promoter activity. With the survivin promoter, there was a significant difference in luciferase expression between the lung cancer cell lines and normal cell lines (P ¼ 0.015), but the expression level was much weaker than with the CMV promoter ( Figure 1b ). However, the survivin-VISA vector greatly enhanced the survivin promoter activity with an average fold of 31 ± 18 and up to 65-fold compared with the survivin promoter alone and even stronger than or comparable to CMV activity in most of the lung cancer cell lines by dual-luciferase assay (Figure 1c ). Similar results were also observed when the luciferase activity was normalized by protein level (data not shown). Most importantly, the VISA vector was able to selectively amplify the survivin promoter in lung cancer cells but not in various normal cells (P ¼ 0.028). The amplified promo-ter activity of survivin-VISA is stronger or equal to the activity of CMV in lung cancer cells but still remains much weaker in normal cells. Thus, the survivin-VISA vector indeed selectively enhanced the transgene expression in lung cancer cells, but remained low expression in normal cells. p53 has been described to negatively regulate the survivin promoter (Hoffman et al., 2002) . Hence, the p53 status could be one factor predetermining transgene expression through the survivin-VISA vector. To address this, we checked the p53 status in the lung cancer cell lines from the reported literature (Hay et al., 1996; Tsai et al., 2006) , listed in the Figure 1c . Indeed, the transgene expression from survivin-VISA vector was lower than that from CMV promoter in three lung cancer cell lines, CRL5802, CRL5806 and A549, harboring wild-type p53, whereas the level was higher or comparable to CMV promoter activity in other lung cancer cells with mutant p53. Therefore, the functional p53 status could be one factor predetermining transgene expression through the survivin-VISA. We also investigated other factors, such as mitosis regulator, Cdc2 (Nigg, 2001) and proliferation rate for their potential activity to affect survivin-VISA driven transgene expression. The results suggest that they are not related to the expression efficacy of transgene from the survivin promoter with correlation coefficience of 0.52 and 0.07, respectively (Supplementary Figure 1 ).
Cancer-specific targeting of survivin-VISA promoter in vivo To examine whether the activity and specificity of survivin-VISA is still retained in vivo, the CMV-Luc and survivin-VISA-Luc (SV-Luc) constructs ( Figure 1a ) were intravenously delivered by liposome (Templeton et al., 1997) to tumor-free and tumor-bearing severe combined immunodeficient (SCID) mice in orthotopic lung cancer xenograft animal models. Bioluminescent imaging revealed a strong signal in the thoracic area of mice treated with CMV-Luc construct in tumor-free and tumor-bearing mice but a low signal in mice treated with SV-Luc construct (Figure 2a upper). To monitor the source of signal more precisely, the mice were killed immediately after in vivo imaging and their organs were dissected for ex vivo imaging (Figure 2a lower) . In CMV-Luc-injected groups, the quantified photon signal showed the high values in the lungs from tumor-free and tumor-bearing mice, whereas very low values in the lungs from SV-Luc-injected tumor-free and tumor-bearing mice. Immunohistochemical analysis also showed strong luciferase expression in both normal lung tissue and tumor tissues in the CMV-Lucinjected group, in contrast to very low luciferase expression in lung normal tissue but strong expression in tumor tissues in SV-Luc-injected group (Figure 2b) . This confirmed the ex vivo imaging results that the CMV promoter strongly drove luciferase expression in both normal lung and lung tumor tissue, although the SV expression vector selectively drove luciferase expression in the lung tumor tissue. The in vivo data showed that the transgene expression in survivin-VISA vector is more lung cancer specific than CMV vector and this vector may be suitable for gene therapy.
Therapeutic gene BikDD driven by the survivin-VISA promoter inhibits the lung cancer cells growth in vitro To examine whether the survivin-VISA vector can be used for gene therapy to drive a therapeutic gene to Targeted BikDD gene therapy inhibits lung cancer Y-P Sher et al selectively kill lung cancer cells, we constructed CMV-BikDD and survivin-VISA-BikDD (SV-BikDD) plasmids ( Figure 3a ). The control vector alone was used as control group (Ctrl). The expression of BikDD driven by CMV or SV was detected by western blot after 24-h transient transfection in F4 lung cancer cells ( Figure 3b ). We then examined whether SV-BikDD plasmid had selective killing activity in lung cancer cells. Eleven lung cancer cell lines and six normal cell lines were transiently cotransfected with Ctrl, CMV-BikDD or SV-BikDD plus pRL-TK (the indicator for transfection efficiency control), and the Renilla luciferase activity was detected ( Figure 3c ). The relative cell viability was measured by setting Ctrl group in each cell lines to 100%. We found that CMV-BikDD exhibited a strong killing effect in both lung cancer cell lines and normal cells (P ¼ 0.19), although SV-BikDD induced a significant cytotoxic effect in cancer cells, and a weak effect in normal cells (P ¼ 0.006), indicating that the survivin-VISA vector drove BikDD expression selectively in lung cancer cells in vitro.
Survivin-VISA-BikDD inhibits tumor growth and prolongs mouse survival time in orthotopic models of F4-Luc and H1299-Luc xenografts
To evaluate the antitumor effects of SV-BikDD in human lung cancer in vivo, we established an orthotopic animal model by intrathoracic injection with human lung cancer cells, F4-Luc in SCID mice. Mice were treated with systemic delivery of liposomal DNA complex and luciferase activity was measured to reflect the tumor size with IVIS imaging system without killing them. The signal increased much more slowly in the CMV-BikDD and SV-BikDD treatment groups than the Ctrl group (Po0.01), indicating that both CMV-BikDD and SV-BikDD treatment inhibited tumor growth ( Figure 4a ). The survival curve also showed that CMV-BikDD and SV-BikDD significantly prolonged the survival time compared with the Ctrl group (Po0.01) ( Figure 4b ). Both of the CMV-BikDD and SV-BikDD treatment groups expressed BikDD mRNA in the lung tissue from mice bearing lung cancer as shown using reverse transcriptase PCR after treatment (Figure 4c ), which shows a higher BikDD expression driven by SV in lung tissue than CMV but no BikDD expression in the liver. Endogenous Bik was undetectable from all tissue RNA, although the primer set could amplify the Bik fragment from plasmids (data not shown). We also used another orthotopic xenograft animal model with H1299-Luc lung cancer tumors to determine the therapeutic effect of the plasmids. Figure 5a showed that SV-BikDD treatment inhibited the tumor growth more strongly than CMV-BikDD and Ctrl groups (Po0.05). In addition, SV-BikDD treat- (Figure 5b ). The mRNA level of BikDD driven by survivin-VISA vector was also higher than that from CMV vector in lung but not in liver, similar to the results shown in Figure 4c (data not shown). We then asked whether SV-BikDD gene therapy was able to prolong the survival of mice suffering from metastatic lung cancer. To examine this, SCID mice were intravenously injected with H1299-Luc lung cancer cells to mimic metastatic circulating cancer cells and then treated with systemic delivery of liposomal DNA complex. Although both CMV-BikDD and SV-BikDD treatment prolonged the survival time compared with Ctrl group (Figure 5c ), the survival curve of SV-BikDD was more significant than CMV-BikDD with P-values of 0.01 and 0.05, respectively. Thus, SV-BikDD suppressed tumor growth and prolonged survival time more effectively than did CMV-BikDD in multiple orthotopic models of human lung cancer in immunodeficient mice. To determine whether SV-BikDD is also effective in immunocompetent mice, we used a syngeneic cancer model. The mouse lung cancer cell line, TC1, was used to establish a syngeneic cancer model in C57BL/6 mice. As shown in Supple- Targeted BikDD gene therapy inhibits lung cancer Y-P Sher et al mentary Figure 2 , expression of BikDD driven by the survivin-VISA vector inhibited tumor growth more effectively and significantly than that driven by CMV promoter compared with Ctrl treatment in mouse TC1 lung cancer syngeneic models. Thus, the potent therapeutic efficacy of SV-BikDD gene therapy can also be observed in immunocompetent mice.
Survivin-VISA-BikDD has no acute toxicity compared with CMV-BikDD
A critical question raised in gene therapy is whether therapeutic plasmids for cancer treatment are toxic to normal cells/tissue. To evaluate whether survivin-VISA-BikDD treatment is safer than CMV-BikDD, a single high dose of 50 mg plasmid DNA was injected through the tail vein of Balb/c mice with normal immunity. All of the animals survived at this dosage and blood samples were collected to determine the serum levels of liver aspartate aminotransferase (AST), alanine aminotransferase (ALT) and blood urea nitrogen (BUN) (Figure 6a ). BUN levels were not elevated at any measurement time point (data not shown), indicating a lack of nephrotoxicity. Treatment with Ctrl and SV-BikDD did not increase the level of AST and ALT; however, serum level of AST and ALT in CMV-BikDD treatment group were readily detectable on day 1 and decreased on day 2, indicating that CMV-BikDD caused severe acute liver toxicity. To assess apoptosis in vivo, mice were killed on day 3 and the apoptosis was determined in the lung and liver using the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) assay (Figure 6b ). CMV-BikDD treatment led to remarkable amount of apoptosis in the normal lung and liver tissue compared with Ctrl and SV-BikDD treatment from the figure. After analysis, CMV-BikDD treatment significantly induced high percentage of apoptotic cells in normal lung and liver tissue compare with Ctrl treatment (Po0.01), but SV-BikDD treatment did not. Taken together these results indicate that CMV-BikDD treatment can lead to normal lung and liver toxicity, although SV-BikDD treatment may be safer for gene therapy.
Discussion
Evidence from studies of in vitro human cells and in vivo xenograft animal models with human cancer cells have revealed that inhibiting the function of survivin in human cancer cells can suppress tumor growth with little toxicity to normal cells/organs (Altieri, 2003b; Li and Ling, 2006) . Our study here also shows that survivin promoter is specifically activated in lung cancer cell lines (Figure 1b) , indicating survivin is a cancer-specific promoter although the activity is weaker than CMV promoter and limits its application in gene therapy. Our developed VISA system resolves this problem by enhancing the survivin promoter activity in vitro in lung cancer cell lines and in vivo in lung tumor tissue of mice but remaining low in normal cells (Figures 1c and 2b) .
In fact, the VISA system can enhance survivin promoter activity in both lung cancer cells (0.09-1.89-fold) and normal cells (0.005-0.124-fold) to about 20-25-fold with CMV activity set to 1. However, as survivin is a cancer-specific promoter, the amplification from VISA made the activity level of survivin-VISA vector to become comparable or higher to CMV promoter in lung cancer cells, but in normal cells, survivin-VISA was still much weaker than that of the CMV promoter ( Figure 1c ). Thus, it is possible for the VISA system to serve as a powerful tool for gene therapy to overcome the typical promoter weakness of cancer-specific promoters as compared with CMV that limits their applications. Combining the cancer-specific promoter with the VISA system might enable novel strategies to treat different cancers without toxicity to normal human tissues. The survivin-VISA vector was specifically activated in lung cancer cells but low in normal cells (Figure 1c) and was able to selectively kill cancer cells, but not normal cells, with the exception of HBEC3KT cells (Figure 3c ). The HBEC3KT cells were established by serially transfecting with retroviral constructs containing cyclin-dependent kinase (CDK) 4 and human telomerase reverse transcriptase in human bronchial epithelial cell (HBEC) lines, resulting in continuously growing cultures (Ramirez et al., 2004) . CDK4 knockdown or inhibition has been reported to induce downregulation of survivin protein and survivin mRNA in pancreatic cancer cells (Retzer-Lidl et al., 2007) , which indicated CDK4 expression is correlated with survivin expression and may activate survivin promoter activity. This may explain why the survivin-VISA vector activated transgene expression in HBEC3KT and had a stronger killing effect than in the other normal cell lines.
Although both SV-BikDD and CMV-BikDD were able to prolong survival in the F4-Luc mouse model (Figure 4b ), there was a significant therapeutic effect with SV-BikDD treatment, but only a low therapeutic effect with CMV-BikDD treatment in H1299-Luc animal model (Figures 5a and b) . On the basis of the promoter activity normalized with total protein, the CMV promoter activity in F4 cells was higher than that in H1299 cells, with values of 1.41 Â 10 9 and 1.05 Â 10 9 RLU/mg, respectively. This may cause the better therapeutic effect of CMV-BikDD treatment in F4-Luc mouse model than in H1299-Luc mouse model. However, SV-BikDD treatments inhibited tumor growth and prolonged survival time in both orthotopic lung cancer animal models (Figures 4 and 5) . Furthermore, our data showed that mice treated with SV-BikDD survived longer than those treated with CMV-BikDD in the animal model of circulating metastatic cells (Figure 5c ). This novel strategy offers an opportunity to target circulating metastatic cancer cells or dormant tumor cells. Thus, SV-BikDD may be more advantageous for lung cancer than CMV-BikDD as metastasis is the major cause of death in lung cancer patients.
Materials and methods
Cell lines
The following cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA): human lung cancer cell lines (NCI-H520, A549, NCI-H2170, HTB54, H1299), immortalized normal mammary epithelial (184A1, MCF-10A), normal lung fibroblasts (WI-38), immortalized normal lung epithelial (HBE4-E6/E7). Immortalized normal lung epithelial cells (HBEC-3KT) were kindly provided by Dr John D Minna (Ramirez et al., 2004) . Other human lung cancer cell lines, CRL-5802, CRL-5806, CL1-0, CL1-5, F4, H928 and H2981, were generated from the National Taiwan University Hospital. Before use, all cell lines were tested and found to be free of Mycoplasma infection.
Construction of plasmids
To construct the survivin-VISA-Luc plasmid, the human survivin gene promoter (from our previous construct, pSRVN-Luc) (Chen et al., 2004) was amplified, digested with SpeI/EcoRV and inserted into pGL3-C-VISA-Luc (Xie et al., 2007) . To construct the therapeutic plasmids, we replaced the luciferase gene with BikDD, which was digested with BglII/NheI and inserted. Then the pGL3 backbone (ampicillin-resistant gene), except the survivin-VISA-BikDD fragment, was changed to pUK backbone (kanamycin-resistant gene) through NotI and SalI ligation for antibiotic replacement.
Evaluation of promoter activity and cytotoxicity
To normalize transfection efficiency, we used the dual-luciferase reporter assay system according to the manufacturer's instructions (Promega, Madison, WI, USA). Briefly, the detected promoter reporter plasmids: pGL3-CMV-Luc or pGL3-survivin-VISA-Luc was cotransfected with the internal plasmid, pRL-TK. Cells were grown to about 80% confluent in 24-well plates and then, transiently transfected with 0.8 mg of tested plasmid DNA with 20 ng of pRL-TK by using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The luciferase activity from cell lysate was determined after 48 h in FB12 Luminometer (Berthold Technologies, Bad Wildbad, Germany). The dualluciferase ratio was presented as the luciferase activity of the tested plasmids divided by the luciferase activity of pRL-TK.
In cytotoxicity, pRL-TK was also used as a reporter gene in all experiments. The luciferase activity of control group (pUK21) was set as 100% in each cell line to detect the killing effect of therapeutic plasmids, pUK-CMV-BikDD and pUK-survivin-VISA-BikDD.
Stable cell lines expressing firefly luciferase F4 and H1299 cells were transfected with pcDNA-Luc-Neo and selected with G418 (1 mg/ml). Ten individual clones with a high-level luciferase activity were mixed as F4-Luc or H1299-Luc stable cell lines.
Animal models of lung cancer and treatments in vivo CB17-SCID mice (BioLASCO, Yi-Lan, Taiwan), at 6-8 weeks of age, were used for human xenograft tumor animal model. The orthotopic lung cancer models of F4-Luc and H1299-Luc were established by inoculating with a suspension of cells through intrathoracic or intravenous injection (McLemore et al., 1988) . After inoculation of cancer cells, the mice were imaged with the IVIS system and then randomly assigned in three groups. Therapeutic plasmids were purified with an Endo-free Mega Prep Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Plasmid DNA was dissolved in endotoxin-free TE buffer. The amount of endotoxin in plasmids was determined by a chromogenic Limulus amoebocyte clotting assay (QCL-1000 kit, BioWhittaker, Walkersville, MD, USA) and in o10 endotoxin units/ mg of DNA. HLDC (Hung lab modified DOTAP:cholesterol) was produced in our laboratory according to Dr Nancy Tempeton's protocol (Templeton et al., 1997) . The mouse received intravenous injection of 100 ml of DNA:HLDC complex containing 25 mg of DNA each time, twice a week and for a total of 6-8 times.
IVIS system and quantification
Mice tumor size was imaged by IVIS Imaging system (Xenogen, Alameda, CA, USA). Mice were anesthetized with a mixture of oxygen and isoflurane and intraperitoneally injected with 100 ml of D-luciferin (Xenogen; 30 mg/ml in phosphate-buffered saline). Later at 10 min, mice underwent imaging with the IVIS imaging system and analysed with Living Imaging software.
Reverse transcriptase PCR of BikDD
Total RNA was extracted from the lung and liver organs 2 days after the last treatment using the TRIzol reagent (Invitrogen) according to the manufacturer's protocol. Extracted RNA was reverse transcribed using oligo(dT) primer and Superscript III reverse transcriptase. The primers used for PCR are: BikDD-For: 5 0 -ATGGAGGTTCTTGGCATG GATGACGA-3 0 ; BikDD-Rev: 5 0 -AGGTGCAGGCCCCCG CTGAGCAGCGG-3 0 ; Bik-For: 5 0 -ATGGAGGTTCTTGG CATGACTGACTC-3 0 ; Bik-Rev is the same to BikDD-Rev; HPRT-For: 5 0 -GGAGCGGTAGCACCTCCT-3 0 ; HPRT-Rev: 5 0 -CTGGTTCATCATCGCTAATCAC-3 0 . A 1-ml aliquot of cDNA product was used for PCR amplification in a 50 ml reaction containing10 pmol of forward and reverse primers, 0.2 mM dNTPs, 1 Â Taq PCR reaction buffer with 1.5 mM MgCl2 and 2 U of Taq DNA polymerase (Roche, Indianapolis, IN, USA) using 35 cycles at 94 1C for 15 s, 58 1C for 30 s and 68 1C for 1 min, and a final 5-min extension at 68 1C. Plasmids containing BikDD or Bik were used as positive control.
Immunohistochemical stain
The lung tumor and other tissues dissected from mice were fixed in 10% neutral-buffered formalin and embedded in paraffin wax. Sections of 5 mm thickness were cut and stained with hematoxylin and eosin. Immunostaining for firefly luciferase was performed as our previous protocol (Xie et al., 2007) by using the goat anti-firefly luciferase antibody (Abcam, Cambridge Science Park, Cambridge, UK), horseradish peroxidase-conjugated avidin biotin complex (ABC) from the Vectastain Elite ABC Kit (Vector Laboratories, Inc., Burlingame, CA, USA) and AEC chromogen (Vector Laboratories). The sections were counterstained with hematoxylin and mounted.
In vivo apoptosis assays
To identify tissue undergoing apoptosis after BikDD expression, an in situ TUNEL assay (BioVision, Mountain View, CA, USA) was carried out according to the manufacturer's instructions. The percentage of apoptotic cells were analysed by random selecting four fields.
Acute toxicity analysis
Balb/c mice were used for acute toxic effects induced by high-dose systemic administration of DNA (50 mg)-HLDC complex. Mice were anethetized and blood collected by retro-orbital bleeding using a heparinized microcapillary tube. Levels of serum AST, ALT and BUN were measured by using assay kits (Roche).
Statistical analysis
Student's t-test was used to compare the different expression or cytotoxicity effect in cancer and normal group. All statistical tests were two sided. Survival curves were obtained by the Kaplan-Meier method. The difference of survival time between two groups was analysed with the log-rank test. The significance level was set at Po0.05.
